A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Zedao Liu(Peking University), Chen Chang(Tongji University), Xiangjie Li(Guangdong University of Technology), Lishan Peng(Guangdong Academy of Medical Sciences), Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Sijin Cheng(Jilin Electric Power Research Institute (China)), Chang Zou(Jinan University), Minglei Yang(Sun Yat-sen University), Qianqian Gao(Shenzhen Bay Laboratory), Liang Zhao(Southwest Jiaotong University), Hui Peng(Guangxi Zhuang Autonomous Region Health and Family Planning), Yongjun Guo(Tianjin Agricultural University), Honghao Fu(Jining First People's Hospital), Zhenlin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyan Liu(Sun Yat-sen University), Chang Liu(Xiamen University), Guangjian Zhang(First Affiliated Hospital of Xi'an Jiaotong University), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Zhigang Tian(University of Science and Technology of China), Wenjie Zhang(Peking University), Yang Li(Lanzhou University), Lei Zhang(Peking University), Yongjie Wang(Qingdao University), Chang Chen(The First People's Hospital of Shunde), Xiaowei Chen(Army Medical University), Chao Zhang(Sun Yat-sen University), Dingcheng Yi(Peking University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Li‐Xu Yan(Sun Yat-sen University), Yufei Bo(Peking University), Ya‐Wen Chen(University of Science and Technology of China), Qingyuan Cai(Peking University), Qi Lu(Peking University), Junqi Wu(Shanghai Pulmonary Hospital), Xueda Hu(Peking University), Wei Tang(Shandong University), Xiaoshi Ma(Shenzhen Second People's Hospital), Ben‐Yuan Jiang(Guangdong Academy of Medical Sciences), Yang Qu(East China Normal University), Guangyu Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Linnan Zhu(Southern Medical University), Shun He(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Long Xu(Tongji University), Hongtao Fan(Peking University), Wanting Zhang(Peking University), Yuxuan Sun(Chinese University of Hong Kong, Shenzhen), Yi Zhang(Jilin University), Deping Zhao(Tongji University)
Cited by 103
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k